Finerenone is a potential first-in-class investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that works on the pathway of MR overactivation, a key contributor to disease progression in patients with chronic kidney disease and type 2 diabetes FIDELIO-DKD is the first […]
Tag: Bayer
Bayer Phase IV Study Met its Primary Endpoint in PAH Patients Who Had Transitioned to Adempas® (riociguat) After Insufficient Response to PDE5 Inhibitors
Data presented as a late-breaker during a virtual ALERT session at the annual meeting of the European Respiratory Society Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH) WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer […]
CORRECTING and REPLACING FDA Approves Gadavist® (gadobutrol) Imaging Bulk Package
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite. INDIANOLA, Pa.–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. The updated release reads: FDA […]
Bayer Names Lori Moore as Vice President, Head of U.S. Pharmaceutical Communications
WHIPPANY, N.J.–(BUSINESS WIRE)–Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today. Moore spent the last six years in senior communications roles at Deloitte, […]
Sensyne Health Signs Collaboration Agreement with Bayer to Accelerate the Development of New Treatments for Cardiovascular Disease using Clinical Artificial Intelligence
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is […]
FDA approves Bayer’s Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease
WHIPPANY, N.J., July 15, 2019 /PRNewswire/ — Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Gadavist® (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients […]
Sensible Medical Innovations Licenses ReDS™ Technology to Bayer
NETANYA, Israel, May 28, 2019 /PRNewswire/ — Sensible Medical Innovations and Bayer successfully signed an agreement making Bayer, Sensible’s largest customer in Europe. Bayer will use Sensible ReDS™ technology as an exploratory device-derived biomarker to monitor lung congestion in a clinical trial (ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03901729). The ReDS […]
Broad and Bayer Expand Partnership, Launching New Research Effort to Develop Therapies for Heart Failure
CAMBRIDGE, Mass., June, 29, 2018 /PRNewswire/ — The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new therapies for heart failure. According to the American Heart Association, […]
Bayer (BAY) Release: In Canadian-Led Phase III Clinical Study, Xarelto® When Combined With ASA Significantly Lowered The Combined Risk Of Stroke, Cardiovascular Death, And Heart Attack In Patients With Chronic Coronary Or Peripheral Artery Disease By 24%
Bleeding rates were low, and while major bleeding was increased, notably, there was no significant increase in intracranial or fatal bleeding1. This combination regimen demonstrated a substantial improvement in net clinical benefit of 20%1. Data from Canadian-led COMPASS study, […]